1. Home
  2. Companies
  3. RHY
  4. Material Events

Rhythm Biosciences (ASX:RHY) — Material Events

ASX:RHY · 21 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major 1 article Significant 16 articles Notable 4 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
16
Rhythm Biosciences Validates ColoSTAT®, Secures Genetype Partnership, and Prepares for FY26 GrowthMedium
Rhythm Biosciences advances ColoSTAT® commercialisation, secures Genetype partnership and funding, announces board changes
31 July 2025 ·Quarterly Cash Flow and Business Update ·85
Rhythm Biosciences Secures Key Accreditation for ColoSTAT® Test, Paving Way for Market LaunchMedium
Rhythm Biosciences’ ColoSTAT® test gains NATA accreditation, advancing commercial launch and reimbursement prospects
9 Mar 2026 ·Regulatory Update ·85
Rhythm Biosciences Hits First ColoSTAT Sale and NHS Evaluation MilestoneMedium
Rhythm Biosciences achieves first ColoSTAT® sale, advances NHS evaluation, and expands geneType™ partnerships in Q3 FY26
30 Apr 2026 ·Appendix 4C and Business Update ·85
Rhythm Biosciences Launches geneType™ in Southeast Asia via Digistain DealMedium
Rhythm Biosciences Signs Distribution Deal with Digistain to Launch geneType™ in Southeast Asia
4 Mar 2026 ·Distribution Agreement ·80
Rhythm Biosciences Raises $3.75M to Launch ColoSTAT® and Expand geneType™Medium
Rhythm Biosciences launches $3.75M placement to fund ColoSTAT® launch and geneType™ expansion
18 Aug 2025 ·Capital Raising ·80
Rhythm Biosciences Validates ColoSTAT Test, Eyes Commercial LaunchMedium
Rhythm Biosciences completes ColoSTAT validation and seeks NATA ISO15189 accreditation for commercial launch
26 Aug 2025 ·Regulatory Update ·80
Rhythm Biosciences Accelerates ColoSTAT® Launch with $3.75m Capital BoostMedium
Rhythm Biosciences advances ColoSTAT® commercialisation, secures $3.75m capital raise, and reports strong Genetype growth in Q1 FY26
29 Oct 2025 ·Appendix 4C Quarterly Cash Flow and Business Update ·80
Rhythm Biosciences Launches ColoSTAT® Blood Test Commercialisation After ISO UpgradeMedium
Rhythm Biosciences launches commercialisation of ColoSTAT® colorectal cancer blood test after ISO accreditation update
12 Dec 2025 ·Commercialisation Announcement ·80
Rhythm Biosciences Secures $3.75M to Launch ColoSTAT® Cancer TestMedium
Rhythm Biosciences to raise $3.75M via placement to launch ColoSTAT® colorectal cancer test
18 Aug 2025 ·Capital Raising ·80
Rhythm Biosciences’ ColoSTAT® Kits Confirm Breakthrough in Colorectal Cancer DetectionMedium
Rhythm Biosciences' ColoSTAT® Kits Achieve Breakthrough Clinical Performance Across All Colorectal Cancer Stages
4 Aug 2025 ·Product Development Update ·80
Rhythm Biosciences Enrolls First Physician in ColoSTAT Access ProgramMedium
Rhythm Biosciences launches ColoSTAT Access Program with first physician enrolment, advancing commercial deployment
11 Feb 2026 ·Commercial Deployment Announcement ·80
Rhythm Biosciences Unveils $3.75M Placement with 52.5M Options, Awaiting Shareholder NodMedium
Rhythm Biosciences launches $3.75M placement with 52.5M options offer, subject to shareholder approval
18 Aug 2025 ·Prospectus ·75
Rhythm Biosciences Validates ColoSTAT® Test Pathway, Poised for Rapid Scale-UpMedium
Rhythm Biosciences completes first commercial ColoSTAT® test sale, ready to scale
11 Mar 2026 ·ASX Announcement ·75
Rhythm Biosciences Locks in Multi-Year Manufacturing Deal for ColoSTAT® KitsMedium
Rhythm Biosciences Secures Multi-Year Manufacturing Deal with Quansys for ColoSTAT® Kits
3 Feb 2026 ·Commercial Manufacturing Agreement ·75
Rhythm Biosciences Navigates $2.26M Loss Amid ColoSTAT Commercial BreakthroughMedium
Rhythm Biosciences reports $2.26M half-year loss amid ColoSTAT commercial launch and geneType expansion
18 Feb 2026 ·Appendix 4D Half-Year Report ·75
Rhythm Biosciences Expands ColoSTAT® Reach with 4Cyte Pathology DealMedium
Rhythm Biosciences partners with 4Cyte Pathology to expand ColoSTAT® colorectal cancer test distribution across eastern Australia
17 Feb 2026 ·Commercial Agreement Announcement ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.